metformin with glp 1 New aspects of an old drug: as a glucagon-like peptide (GLP-1) enhancer and sensitiser | Diabetologia Frontiers | Understanding the action

Intensive therapy resulted in a reduced risk of albuminuria and eGFR decline, extending beyond the randomisation period, indicating the importance of early glycaemic control in preventing long-term adverse kidney outcomes [18]

Given that the comorbidity rate of anxiety disorders and depression is as high as 60% [6], it is appropriate to study these conditions concurrently

Because of the increased risk of adverse reactions, it is not recommended for use in the absence of diabetes

Expanded obesity drug coverage can increase Medicaid spending and put pressure on overall state budgets, and states are now facing tighter budget conditions and longer-term fiscal uncertainty, due in part to the federal Medicaid cuts in the 2025 reconciliation law, causing state Medicaid programs to re-evaluate their obesity drug coverage

Diabetes Care 44(3):765773

The method for injecting a GLP-1 is mostly the same, regardless of whether youre injecting into the thigh, abdomen, or upper arm